Form 4 for LQDA Liquidia Corp
Accepted 2021-11-12 00:00:00 ET · period of report 2021-11-10 · accession 0001104659-21-138300 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-12 | 2021-11-10 | LQDA | Moomaw Scott | SVP, Commercial | M - OptEx | — | +7,650 | 7,650 | New | — |
| D | 2021-11-12 | 2021-11-10 | LQDA | Moomaw Scott | SVP, Commercial | A - Grant | $0.00 | -7,650 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-10 | M | A | 7,650 | — | 7,650 | D | — | — | (F1) Each performance stock unit (PSU) converts into one share of common stock of the Issuer. |
| 2 | Derivative | Performance Stock Units | 2021-11-10 | A | D | 7,650 | $0.00 | 0 | D | — · — to — | 7,650 Common Stock | (F1) Each performance stock unit (PSU) converts into one share of common stock of the Issuer. (F2) On January 19, 2021, the reporting person was granted 7,650 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. |